Ownership and insider activity for Ardelyx, Inc. (ARDX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Ardelyx, Inc. is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of innovative medicines. The company primarily focuses on addressing gastrointestinal (GI) and cardiorenal conditions, serving patients both domestically in the United States and across international markets. Its flagship product candidate is tenapanor.
Price
| Price | $3.39 |
| Market Cap | $837M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-21 | Hohenleitner Susan | S-Sale | 1,558 | $6K |
| 2026-08-21 | Reilly Joseph James | S-Sale | 2,872 | $11K |
| 2026-08-21 | Reilly Joseph James | S-Sale | 1,110 | $4K |
| 2026-08-21 | Bishop John E | S-Sale | 17,281 | $67K |
| 2026-08-21 | Bishop John E | S-Sale | 2,469 | $10K |
| 2026-08-21 | Brady James Parker | S-Sale | 1,976 | $8K |
| 2026-08-21 | Brady James Parker | S-Sale | 13,160 | $51K |
| 2026-08-21 | Foster Eric Duane | S-Sale | 2,598 | $10K |
| 2026-08-21 | Foster Eric Duane | S-Sale | 3,389 | $13K |
| 2026-08-21 | Foster Eric Duane | S-Sale | 2,575 | $10K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $74.6M | $75.4M | $78.8M | $181.1M | $91.0M | $72.4M | $96.1M | $21.5M | $64.9M | $68.0M |
| Short-term Investments | $126.2M | $58.6M | $89.3M | $66.4M | $95.5M | $44.3M | $27.8M | $162.8M | $185.2M | $196.7M |
| Receivables | 0 | $10.8M | $5.1M | $750000 | 0 | $502000 | $7.7M | $22.0M | $57.7M | $71.8M |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | $3.3M | $12.4M | $21.2M | $17.7M |
| Total Current Assets | $204.0M | $149.9M | $177.7M | $252.4M | $195.2M | $133.6M | $153.6M | $246.1M | $356.5M | $382.3M |
| Property, Plant & Equipment | $9.0M | $8.0M | $5.6M | $7.4M | $4.2M | $15.1M | $10.5M | $6.6M | $3.9M | $7.0M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $213.1M | $157.9M | $183.3M | $259.8M | $201.6M | $149.9M | $190.1M | $297.6M | $435.8M | $501.6M |
| Accounts Payable | $5.6M | $3.9M | $1.1M | $2.2M | $5.6M | $4.3M | $10.9M | $11.1M | $16.0M | $19.2M |
| Short-term Debt | 0 | 0 | 0 | $3.8M | $6.3M | $32.3M | $26.7M | 0 | 0 | $1.5M |
| Total Current Liabilities | $19.2M | $17.9M | $17.7M | $22.2M | $28.4M | $52.8M | $65.6M | $50.4M | $77.8M | $88.6M |
| Long-term Debt | 0 | 0 | $49.2M | $48.8M | $46.6M | 0 | 0 | $49.8M | $150.9M | $206.5M |
| Total Liabilities | $20.0M | $18.6M | $67.5M | $73.1M | $75.5M | $67.3M | $91.7M | $130.8M | $262.5M | $334.7M |
| Retained Earnings | -$213.9M | -$278.2M | -$365.5M | -$460.5M | -$554.8M | -$712.9M | -$780.1M | -$846.2M | -$885.3M | -$946.9M |
| Total Equity | $193.2M | $139.3M | $115.8M | $186.7M | $126.1M | $82.6M | $98.3M | $166.8M | $173.3M | $166.9M |
| Total Debt | 0 | 0 | $49.2M | $57.3M | $55.4M | $45.5M | $36.5M | $56.0M | $153.4M | $211.6M |
| Net Debt | -$200.8M | -$134.0M | -$118.9M | -$190.2M | -$131.0M | -$71.2M | -$87.4M | -$128.3M | -$96.7M | -$53.1M |
| Working Capital | $184.8M | $132.0M | $160.0M | $230.2M | $166.8M | $80.8M | $88.0M | $195.7M | $278.6M | $293.7M |
Financial Health
| Debt / Equity | 1.72 |
| Current Ratio | 3.34 |
Profitability
| Return on Equity | -36.00% |
| Return on Invested Capital | -7.96% |
| Return on Assets | -9.67% |
| Gross Margin | 93.96% |
| Operating Margin | -7.86% |
| Net Margin | -12.35% |
Related companies: BCRX · MAZE · NTLA · PHVS · STOK · SYRE · TRVI
Explore sector: Healthcare · Biotechnology
More sections of ARDX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks